Novel Recombinant Protein UK114 in Stable Polymer Form for Tumour Treatment
Summary
The European Patent Office granted Patent EP3554639A1 to Alberto Bartorelli Cusani for a novel recombinant protein UK114 in stable polymer form designed for the treatment or prevention of malignant solid and systemic tumours. The patent covers pharmaceutical compositions containing the recombinant protein and methods of treatment. The patent is classified under A61K 38/50 and related pharmaceutical categories.
What changed
The EPO granted Patent EP3554639A1 for a novel recombinant protein designated UK114 in stable polymer form. The protein is designed for use in the treatment or prevention of malignant solid and systemic tumours. The patent application was filed by inventor Alberto Bartorelli Cusani and includes multiple IPC classifications related to pharmaceutical compositions and therapeutic applications.
Affected parties including pharmaceutical companies, biotech firms, and research institutions developing cancer treatments should review this patent for potential licensing opportunities or to assess freedom-to-operate for competing therapeutic approaches. The patent provides intellectual property protection across designated European states including Germany, France, the United Kingdom, Italy, Spain, and other EU member states.
What to do next
- Monitor patent portfolio for freedom-to-operate considerations
- Review patent claims for potential licensing opportunities
- Conduct prior art search if developing competing therapies
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NOVEL RECOMBINANT PROTEIN UK 114 IN STABLE POLYMER FORM FOR USE IN THE TREATMENT OR PREVENTION OF MALIGNANT SOLID AND SYSTEMIC TUMOURS
Publication EP3554639A1 Kind: A1 Apr 08, 2026
Applicants
Bartorelli Cusani, Alberto
Inventors
Bartorelli Cusani, Alberto
IPC Classifications
A61K 38/50 20060101AFI20260227BHEP A61P 35/00 20060101ALI20260227BHEP A61K 38/16 20060101ALI20260227BHEP A61K 35/66 20150101ALI20260227BHEP A61K 39/00 20060101ALI20260227BHEP A61P 37/04 20060101ALI20260227BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.